PET-CT for Bone Metastases: — What the Scan Can Miss

A clear FDG PET-CT means no metabolically active lesions were detected by that tracer. It does not rule out sclerotic metastases, which may be present and PET-negative. In prostate cancer, a clear FDG PET-CT is not sufficient to exclude bone spread — ESMO and NCCN recommend bone scintigraphy or PSMA PET-CT for prostate cancer staging for exactly this reason. If your cancer is known to cause sclerotic spread, or if you have bone pain that remains unexplained, ask your oncologist whether additional imaging is needed before treating a clear result as final.

In a lytic lesion, cancer cells activate bone-destroying cells called osteoclasts, which eat away the bone structure and leave gaps visible on imaging. In a sclerotic lesion, cancer cells stimulate bone-forming cells called osteoblasts, which lay down dense bone tissue around them. Lytic lesions are often highly metabolically active, so FDG accumulates and PET-CT detects them. Sclerotic lesions are often metabolically quiet, so FDG does not accumulate and the scan may look normal even when disease is present. The two types require different imaging to find reliably.

Prostate cancer cells release factors that strongly stimulate osteoblasts, producing dense, ivory-white bone lesions. Most other cancers — lung, kidney, thyroid, myeloma — do the opposite, stimulating osteoclasts and causing lytic destruction. Breast cancer can cause both, or a mixed pattern, depending on the subtype. This biological difference is why imaging strategy in prostate cancer diverges from what works for other cancers, and why PSMA PET-CT — which detects a prostate-specific protein rather than glucose metabolism — performs better than FDG in that disease and is now ESMO's preferred staging tool for it.

Tell your oncology team before your next scheduled appointment, not after it. Bone pain — especially in the spine, pelvis, ribs, or femur — is the most common presenting symptom of bone metastases, and a clear FDG PET-CT does not rule out sclerotic spread in cancers that behave that way. Your team may order a bone scan, MRI of the painful area, or plain X-rays depending on your cancer type and the location of pain. Do not assume the pain is muscular or unrelated to your cancer without telling your team first.

CION coordinates PET-CT imaging with partner imaging centres. Whether PSMA PET-CT is available at the centre nearest to you, and whether it is appropriate for your situation, is something your oncologist will address. PSMA PET-CT uses a different tracer to FDG and is specific to prostate cancer — it does not improve detection for other cancer types and should not be requested as a general upgrade. If you have prostate cancer, ask your oncologist directly whether PSMA PET-CT is being considered for your staging or restaging, and which partner centre would coordinate it.

Not automatically. Finding bone metastases changes staging and usually triggers a review of the treatment plan, but it does not mean options have run out. Bone metastases from breast, prostate, and lung cancer, among others, can respond to systemic treatment. Bone-strengthening medications such as bisphosphonates or denosumab are often added to reduce fracture risk and pain. When lesions are near the spinal cord or in weight-bearing bones, radiation oncology or orthopaedic oncology may be involved. Your oncologist will explain what was found and what each option is intended to achieve before any decision is made.